Suchergebnisse - "Entezari-Maleki, Taher"

PubPharm (14)

1

A commentary on "Unexpected sudden rise of human monkeypox cases in multiple non-endemic countries amid COVID-19 pandemic and salient counteracting strategies : Another potential global threat?" (Int J Surg 2022;103:106705)

enthalten in: International journal of surgery (London, England) | 2022

von Khani, E. | Entezari-Maleki, T.

CommentOn: Int J Surg. 2022 Jul;103:106705. - PMID 35697322

2

Fluvoxamine and long COVID-19; a new role for sigma-1 receptor (S1R) agonists

enthalten in: Molecular psychiatry | 2022

von Khani, E. | Entezari-Maleki, T.

CommentOn: Mol Psychiatry. 2022 Apr;27(4):1898-1907. - PMID 34997196

3

New Variants of SARS-CoV-2 and Next Generation of COVID-19 Treatments

enthalten in: Journal of clinical pharmacology | 2022

von Khiali, S. | Entezari-Maleki, T.

4

Hypertensive Crisis Following COVID-19 Vaccination

enthalten in: Journal of clinical pharmacology | 2022

von Khani, E. | Entezari-Maleki, T.

CommentOn: Hypertension. 2021 Jun;77(6):e56-e57. - PMID 33764160

5

The role of antigen-presenting cells in the pathogenesis of COVID-19

enthalten in: Pathology, research and practice | 2022

von Farzi, R. | Aghbash, P. | Eslami, N. | +5

6

Comprehensive review on molnupiravir in COVID-19 : a novel promising antiviral to combat the pandemic

enthalten in: Future microbiology | 2022

von Khiali, S. | Khani, E. | B Rouy, S. | +1

7

SARS-CoV-2 : Receptor and Co-receptor Tropism Probability

enthalten in: Current microbiology | 2022

von Eslami, N. | Aghbash, P. | Shamekh, A. | +4

8

SARS-CoV-2: Receptor and Co-receptor Tropism Probability

enthalten in: Current microbiology | 2022

von Eslami, N. | Aghbash, P. | Shamekh, A. | +4

9

SARS-CoV-2: Receptor and Co-receptor Tropism Probability

enthalten in: Current microbiology | 2022

von Eslami, N. | Aghbash, P. | Shamekh, A. | +4

10

SARS-CoV-2: Receptor and Co-receptor Tropism Probability

enthalten in: Current microbiology | 2022

von Eslami, N. | Aghbash, P. | Shamekh, A. | +4